Rocaglamide A (RocA) typifies a novel class of protein synthesis inhibitors that selectively kill aneuploid tumor cells and repress translation of specific mRNAs. RocA targets eukaryotic initiation factor 4A (eIF4A), the prototypical DEAD-box RNA helicase, and its mRNA selectivity is proposed to ref...
Transcriptomic analysis of synchonized AC16 cells treated with homoharringtonine 1 µM or Rocaglamide A 100 nM for 4h (20h after synchronization) We used microarrays to detail the global programme of gene expression
Rocaglamide A (RocA) typifies a class of protein synthesis inhibitors that selectively kill aneuploid tumor cells and repress translation of specific mRNAs. RocA targets eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase; its mRNA selectivity is proposed to reflect highl...
An iTRQA-based quantitative proteome analysis using liquid chromatography–coupled tandem mass spectrometry was performed to acquire proteome-wide expression data on Triple-negative Breast Cancer (TNBC) cells treated with Rocaglamide A for 24 hours.
An TMT-based quantitative phosphoproteome analysis using liquid chromatography–coupled tandem mass spectrometry was performed to acquire proteome-wide expression data on Triple-negative Breast Cancer (TNBC) cells treated with time-course Rocaglamide A.
